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ABSTRACT
Introduction: Iron deficiency anemia (IDA) is a
common complication of inflammatory bowel
disease (IBD) and can result in reduced quality
of life and increased healthcare costs. IDA is
treated with iron supplementation, either with
oral iron therapy (OI) or intravenous iron for-
mulations, including ferric carboxymaltose
(FCM), iron isomaltoside 1000 (IIM), and iron
sucrose (IS). This analysis compared the cost-
effectiveness of FCM versus IIM, IS, and OI in
terms of additional cost per additional respon-
der in Switzerland.
Methods: A health economic model was
developed to assess the additional cost per
additional responder, defined as normalization
or an increase of at least 2 g/dL in hemoglobin
levels, for FCM versus IIM, IS, and OI. To date,
no single head-to-head trial comparing all
therapies is available, and therefore relative
efficacy data were taken from a published net-
work meta-analysis. Costs of treatment were
calculated in 2020 Swiss francs (CHF) using a
microcosting approach, and included the costs
of iron, healthcare professional time, and con-
sumables. Costs are also presented in euros
(EUR) based on an exchange rate of CHF
1 = EUR 0.94.
Results: Response rates with FCM, IIM, IS, and
OI were 81%, 74%, 75%, and 69%, respectively,
with FCM projected to be the most effective
treatment. FCM was associated with cost sav-
ings of CHF 24 (EUR 23) versus IIM and of CHF
147 (EUR 138) versus IS, and increased costs by
CHF 345 (EUR 324) versus OI. Therefore FCM
was considered dominant versus both IIM and
IS, improving clinical outcomes with cost sav-
ings. FCM was associated with an incremental
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cost-effectiveness ratio of CHF 2970 (EUR 2792)
per additional responder versus OI.
Conclusions: FCM was projected to be the most
cost-effective intravenous iron therapy in
Switzerland, increasing the number of respon-
ders and leading to cost savings for healthcare
payers.
Keywords: Cost; Cost-effectiveness; Inflamma-
tory bowel disease; Iron deficiency anemia;
Switzerland
Key Summary Points
Why carry out this study?
Iron deficiency anemia (IDA) subsequent
to inflammatory bowel disease (IBD) is
associated with reduced quality of life, an
increase in time off work, an increased
frequency of hospitalization, and
increased healthcare costs.
Treatment options for IDA subsequent to
IBD include oral and intravenous iron
formulations, with ferric carboxymaltose
(FCM), iron isomaltoside 1000 (IIM), and
iron sucrose (IS) currently available in
Switzerland.
The present analysis compared the cost-
effectiveness, expressed in terms of
additional cost per additional responder,
of FCM versus IIM, IS, and oral iron
therapy in Switzerland, based on the
differing costs and dosing profiles, and the
differences in clinical efficacy identified in
the recently published network meta-
analysis (NMA).
What was learned from the study?
FCM was considered dominant versus
both IIM and IS, improving clinical
outcomes with cost savings.
FCM was associated with an incremental
cost-effectiveness ratio of CHF 2970
(EUR 2792) per additional responder
versus oral iron therapy.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.13135580.
INTRODUCTION
Inflammatory bowel disease (IBD) is a group of
conditions involving chronic inflammation of
the digestive tract, the most common of which
are Crohn’s disease and ulcerative colitis. A
global study of the prevalence of IBD estimated
the prevalence in Switzerland to be 94.8 cases
per 100,000 population, while an analysis of
gastroenterologist files in the canton of Vaud
suggests that the prevalence of IBD is much
higher at 205.7 cases per 100,000 population
(comprised of 100.7 cases of Crohn’s disease per
100,000 population and 105.0 cases of ulcera-
tive colitis per 100,000 population) [1, 2].
Analysis of insurance data suggests that
approximately 25% of patients with IBD are
hospitalized annually, compared with approxi-
mately 10% of the population without IBD [3].
Anemia is the most frequent complication of
IBD and has been shown to negatively impact
quality of life and cognitive function [4, 5]. In
the majority of cases of anemia subsequent to
IBD, the cause is a combination of iron defi-
ciency anemia (IDA) and anemia of chronic
disease (ACD) [6]. It is estimated that iron defi-
ciency occurs in between 36% and 90% of
patients with anemia with IBD [7]. Iron defi-
ciency and IDA result from a combination of
factors, including chronic blood loss from the
intestinal mucosa, impaired gastrointestinal
absorption (sometimes due to short bowel syn-
drome), reduced dietary intake due to loss of
appetite, and blockage of intestinal iron acqui-
sition [8, 9]. IDA subsequent to IBD is associated
with reduced quality of life, an increase in time
off work, an increased frequency of hospital-
ization, and increased healthcare costs [10].
The aims of iron supplementation in
patients with IDA subsequent to IBD, based on
guidelines released by the European Crohn’s
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and Colitis Organisation (ECCO) and pub-
lished in the World Journal of Gastrointestinal
Pathophysiology, are to replenish iron stores,
normalize levels of hemoglobin, serum ferritin,
and transferrin saturation, avoid the need for
blood transfusion, and improve quality of life
[11, 12]. Available treatment options to achieve
these goals include oral and intravenous (IV)
iron formulations. Oral iron therapy is recom-
mended for patients with mild IDA and clini-
cally inactive IBD, with no history of
intolerance to oral iron administration [11].
The key advantages of oral iron therapy are the
low cost and ease of administration at home.
However, efficacy is limited because of
impaired intestinal iron absorption due to the
underlying IBD, and side effects, such as
abdominal pain, nausea, bloating, and diar-
rhea, can limit adherence. Furthermore, oral
iron therapy can exacerbate IBD, with unab-
sorbed iron causing mucosal damage, genera-
tion of reactive oxygen species causing
oxidative stress in the intestinal tract, and
alteration of the gut microbiota [13–16]. IV
iron products are recommended for patients
with severe anemia (hemoglobin less than
10 g/dL), intolerance or lack of response to oral
iron therapy, active IBD, or where there is a
need for a quicker response and/or longer-term
iron supplementation [11, 12]. IV iron therapy
has been shown to be more effective in terms
of iron replenishment than oral iron therapy.
Additionally, the avoidance of gastrointestinal
side effects allows administration in patients
with active IBD. However, administration of IV
iron products is only possible in a medical
facility (hospital or perfusion unit in a private
practice), and while adverse events with mod-
ern formulations are rarely severe, immediate
access to resuscitation equipment is required
[11]. The IV iron therapies currently available
in Switzerland are ferric carboxymaltose (FCM)
(Ferinject", Vifor Pharma Group), ferric deri-
somaltose/iron isomaltoside 1000 (IIM)
(Monofer", Pharmacosmos A/S), and iron
sucrose (IS) (Venofer", Vifor Pharma Group).
Each IV iron formulation has a specific dos-
ing pattern and schedule outlined in each of the
product labels, resulting in different delivery
patterns in clinical practice. FCM can be
administered in doses up to 1000 mg iron in a
single infusion [17]. When IIM is used, up to
20 mg of iron can be administered per kilogram
of body weight (e.g., 1000 mg of iron can be
administered in a patient weighing 50 kg, but
1200 mg of iron can be administered in a
patient weighing 60 kg) [18]. In contrast, IS
dosing is limited to 200 mg iron per infusion
[19]. A number of studies have compared FCM
with IIM, FCM with IS, and FCM, IIM, and IS,
individually, with oral iron therapy, but no
single trial has compared the efficacy and safety
of all possible treatment options in a single
population [20–26]. However, Aksan et al. con-
ducted a network meta-analysis (NMA) in
which the outcomes from the four existing
randomized controlled trials (RCTs) of FCM,
IIM, IS, and oral iron therapy were combined
and adjusted for differences in study popula-
tions and trial methods [27]. The NMA assessed
the dichotomous variable of treatment
response, where a response was defined in line
with ECCO guidelines as normalization of
hemoglobin levels or an increase of at least 2 g/
dL in hemoglobin. This analysis found that
FCM was significantly more efficacious than
oral iron therapy and was associated with a
numerically greater but not statistically signifi-
cant increase in response rate compared with
IIM and IS (Table 1). Rank probability assess-
ment found that there was an 83% probability
that FCM was the most effective treatment,
with a 14% probability that IIM was the most
effective treatment.
As part of evidence-based healthcare deci-
sion-making, analyses not only of efficacy and
safety but also of value for money are
increasingly taken into account. Cost–utility
analyses take into account costs and quality-
adjusted life expectancy with a new interven-
tion versus current practice, with the aim of
calculating an incremental cost-effectiveness
ratio (ICER), describing the additional cost per
additional quality-adjusted life year (QALY)
gained [28]:
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The calculated ICER can then be compared
with a willingness to pay threshold, to evaluate
whether the new intervention would be con-
sidered good value for money if used in clinical
practice. While cost–utility analyses are con-
sidered the gold standard, robust sources of
information on how treatments affect quality of
life are required. To date, data on how treat-
ments for IDA affect quality of life in patients
with IBD are not available. In such situations, it
is recommended that cost-effectiveness analyses
are performed, assessing outcomes in terms of
‘‘natural units’’. For example, a screening pro-
gram could be assessed on the basis of ‘‘cost per
case detected’’, while a fertility treatment could
be assessed on the basis of ‘‘cost per live birth’’
[29, 30]. When the cost-effectiveness of inter-
ventions for IDA is assessed, the ‘‘natural unit’’
of ‘‘number of patients responding to treat-
ment’’ could be used. The ICER formula can be
adapted to become
While there is no willingness to pay thresh-
old for the additional cost per additional
responder, this approach provides context on
the relative cost-effectiveness of IDA treatments
in patients with IBD, which would not other-
wise be possible, thereby providing useful
information to healthcare decision makers.
To date, no analyses have assessed the cost-
effectiveness of iron treatments for patients
with IDA subsequent to IBD in Switzerland. The
present analysis aimed to address this research
question, comparing the cost-effectiveness,
expressed in terms of additional cost per addi-
tional responder, of FCM versus IIM, IS, and oral
iron therapy in Switzerland, based on the dif-
fering costs and dosing profiles, and the differ-
ences in clinical efficacy identified in the
recently published NMA [27].
METHODS
Approach to Estimating Cost-Effectiveness
Cost-effectiveness was estimated in terms of the
additional cost per additional responder with
FCM versus IIM, IS, and oral iron therapy indi-
vidually over one cycle of treatment, where a
responder was defined on the basis of the ECCO
guidelines as achieving hemoglobin normaliza-
tion or an increase of at least 2 g/dL in hemo-
globin levels. Evaluation of the dichotomous
variable ‘‘response versus no response’’ was
considered an appropriate parameter to mea-
sure efficacy, as use of a continuous variable,
such as mean hemoglobin increase, can be
influenced by baseline hemoglobin levels. A
cost-effectiveness model was prepared in
Microsoft Excel to calculate costs and the per-
centage of patients with IBD and IDA achieving
a response, with FCM, IIM, IS, and oral iron
therapy. To do this, the model generated a
cohort of patients with IDA and IBD, with
patient characteristics sampled based on
defined distributions. This probabilistic
ICER ¼ Costintervention # Costcomparator
Quality-adjusted life expectancyintervention # Quality-adjusted life expectancycomparator
:
ICER ¼ Costintervention # Costcomparator
Number of respondersintervention #Number of responderscomparator
:
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approach, rather than simply using mean val-
ues, allows a representative cohort of patients
with differing characteristics and therefore dif-
ferent iron requirements and different costs of
treatment to be used, as well as capturing the
uncertainty around differences in efficacy
between treatment arms identified by the Aksan
et al. NMA. It results in a spread of cost and
efficacy values, the mean and standard error
(SE) of which can be calculated. A total of 1000
patients were simulated, with characteristics
sampled for each patient, as outcomes were
stable at this number of model iterations. Out-
comes were not projected beyond a 1-year time
horizon, and therefore no discounting was
applied.
Calculation of Costs
Cost of a course of treatment for IDA in patients
with IBD was calculated for each of the 1000
patients with the four interventions in 2020
Swiss francs (CHF). Costs are also presented in
euros (EUR) based on an exchange rate of CHF
1 = EUR 0.94. In each model iteration, patient
hemoglobin and body weight were sampled
based on the two RCTs of FCM included in the
NMA [22, 23]. The mean hemoglobin across the
two RCTs was 9.6 g/dL with a standard error (SE)
0.1 g/dL, while the mean body weight was
66.6 kg with an SE of 0.7 kg. In each iteration,
the sampled patient characteristics were used to
calculate the required iron dose. With FCM this
was calculated using the Ganzoni formula, as is
recommended in the prescribing information in
Switzerland [17]. The formula takes into
account patient body weight, hemoglobin, tar-
get hemoglobin, and iron stores, with iron
stores assumed to be 500 mg and target hemo-
globin assumed to be 15 mg/dL in all patients:
Iron deficit mgð Þ ¼ body weight
& target Hb#Hbð Þ & 2:4
þ iron stores.
In the IIM and IS arms, the simplified dosing
table was used to calculate the required dose
(Table 2), as recommended in the ECCO anemia
guidelines [12]. Following calculation of the
appropriate iron dose, the number of infusions
required to deliver the dose was calculated
based on each of the product labels [17–19].
Costs of infusion of iron were calculated
using a microcosting approach, where the unit
costs of each aspect of medical resource use are
summed to give a total cost. Therefore costs
were calculated from a hospital perspective. The
Table 1 Treatment efficacy: odds ratio for response rate
Odds ratio compared with ferric
carboxymaltose
Lower 95% credible
interval
Upper 95% credible
interval
Iron
isomaltoside
0.69 0.34 1.40
Iron sucrose 0.70 0.48 1.00
Oral iron
therapy
0.53 0.32 0.89
Response was defined as a patient who achieved normalization of hemoglobin levels or an increase in hemoglobin of at least
2 g/dL [27]
Table 2 Simplified dosing table
Hemoglobin (g/dL) Body weight (kg)
< 35 35–70 ‡ 70
\10 500 1500 2000
10–14 500 1000 1500
C 14 500 500 500
Response was defined as a patient who achieved normal-
ization of hemoglobin levels or an increase in hemoglobin
of at least 2 g/dL
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pharmacy costs associated with FCM, IIM, and
IS were based on ex-factory prices (Table 3) [31].
It was assumed that vials of IV iron product
were used in the most cost-efficient manner,
with the most appropriate vial or combination
of vials used to deliver the required dose at the
lowest possible cost. Where a required dose was
less than the complete contents of a vial, the
remainder of that vial was assumed to be
wasted. In addition to the pharmacy costs, the
cost calculation also captured the costs of time
required by a healthcare professional to deliver
the infusion (based on the label for each pro-
duct, capturing preparation time, infusion time,
and post-infusion supervision), giving sets,
cannula, and dressings (Table 4) [32–35]. The
total cost per course of treatment was then
Table 3 Pack contents and pack costs of IV iron formulations
Pack contents Pack cost (CHF) Cost per mg iron (CHF)
Ferric carboxymaltose 5 vials each containing 100 mg iron 28.05 0.28
Ferric carboxymaltose 5 vials each containing 500 mg iron 140.25 0.28
Ferric carboxymaltose 1 vial containing 1000 mg iron 280.50 0.28
Iron isomaltoside 5 vials each containing 100 mg iron 26.87 0.27
Iron isomaltoside 5 vials each containing 500 mg iron 134.33 0.27
Iron isomaltoside 2 vials containing 1000 mg iron 268.67 0.27
Iron sucrose 5 vials each containing 100 mg iron 16.93 0.17
CHF 2020 Swiss francs
Table 4 Resource use associated with infusion of IV iron formulations
Ferric carboxymaltose Iron isomaltoside Iron sucrose
Infusion time (minutes)
\500 mg 6 – –
500–1000 mg 15 – –
\1000 mg – 15 –
[1000 mg – 30 –
\50 mg – – 8
50–100 mg – – 15
100–200 mg – – 30
Preparation time (min) 15 15 15
Observation time (min) 30 30 30
Giving sets required 1 1 1
Cannula required 1 1 1
Dressings required 1 1 1
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calculated by summing the cost of all infusions
with each iron formulation.
The cost of oral iron was calculated based on
a 15-min consultation with a general practi-
tioner, a laboratory blood test, and an 84-day
course of 100 mg ferrous sulfate administered
orally twice daily [31, 36, 37]. This dosing
reflected the oral iron therapy arm of the RCT
included in the NMA which compared FCM
with oral iron therapy [23]. Other studies cap-
tured by the NMA applied various durations of
oral iron therapy, with the study comparing IS
and oral iron therapy applying a dosing sched-
ule of 100 mg ferrous sulfate administered orally
twice daily for 20 weeks, and the studies com-
paring ISM and IS with oral iron therapy using
schedules of 100–200 mg of ferrous sulfate for
8 weeks. Therefore matching to the FCM versus
oral iron therapy RCT reflected the average of
the trials included in the NMA.
Calculation of Efficacy
Efficacy was expressed in terms of the percent-
age of patients achieving a response over one
cycle of treatment, where a responder was
defined based on the ECCO guidelines as
achieving hemoglobin normalization or an
increase of at least 2 g/dL in hemoglobin levels.
In the FCM arm this was based on the weighted
average of the two RCTs of FCM captured in the
Aksan et al. NMA [22, 23, 27]. Over these two
trials, 81% of patients receiving FCM achieved a
response. In each model iteration, this was
sampled based on an SE of 2.1%, derived
assuming a binomial proportion confidence
interval. To calculate the percentage of patients
achieving a response with IIM, IS, and oral iron
therapy, the odds ratio for each comparator
versus FCM was sampled based on the mean
and 95% credible interval (CI) calculated by
Aksan et al. (Table 1). The mean and SE of
patients achieving a response was calculated for
each therapy across all of the model iterations.
Differences between the mean percentages of
responders were used to calculate the number
needed to treat, expressed as the number of
patients who would need to be treated with
FCM instead of the comparator in order to
achieve one additional responder. Number
needed to treat values are conventionally
rounded up to the next integer value.
Calculation of Cost-Effectiveness
The cost-effectiveness of FCM was assessed ver-
sus each of IIM, IS, and oral iron therapy in
turn, with ICERs expressed in terms of addi-
tional cost per additional responder. In each
comparison, the mean cost of a course of
treatment with each intervention was sub-
tracted from the mean cost of a course of
treatment with FCM, and the mean percentage
of responders with each comparator was sub-
tracted from the mean percentage of responders
with FCM. The cost difference was divided by
the difference in response rates to calculate the
ICER. In a cost-effectiveness analysis, an inter-
vention that is both more effective and results
in reduced costs is described as ‘‘dominant’’, and
calculation of an ICER is not appropriate (i.e.,
negative ICERs should not be reported). There-
fore, in comparisons where FCM was projected
to increase response rates and decrease costs
compared with an alternative intervention, no
ICER was calculated.
Scenario Analyses
To evaluate the impact of different methods of
estimating the iron requirement and calculating
costs, a series of scenario analyses were per-
formed. In the base case analysis, the Ganzoni
formula was applied in the FCM arm, with the
simplified dosing table used in the IIM and IS
arms. In a scenario analysis, the Ganzoni for-
mula was applied in all arms.
An alternative to the microcosting approach
was also explored. In Switzerland, TARMED
codes can be used by healthcare providers to bill
their medical activities in an outpatient setting
to insurance companies. These codes take into
account healthcare professional time, as well as
fixed costs of running hospitals/practices. These
codes cover provision of services, but do not
include costs of medications, and therefore
these costs were included using the same
methodology as the base case analysis. Analyses
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were conducted with TARMED codes applied
and the Ganzoni formula used in the FCM arm
and the simplified dosing table used in the IIM
and IS arms, and with the Ganzoni formula used
in all arms. In these analyses, costs were assessed
from an insurance company perspective.
Sensitivity Analyses
As well as the scenario analyses, a series of
sensitivity analyses were conducted to evaluate
the robustness of the model results and the
impact of variation in model inputs. The effect
of varying the odds ratios taken from the NMA
was assessed by preparing analyses with the
upper and lower 95% CIs of the odds ratios for
achieving a response with the comparator ver-
sus FCM. This aims to capture the uncertainty
around the outcomes of the NMA. Body weight
and hemoglobin are the key determinants of
the iron dose required, both when the Ganzoni
formula and when the simplified dosing
table are used. Therefore sensitivity analyses
were performed with the mean body weight
increased by 10 (i.e., to 76.6 kg), and with the
mean hemoglobin increased and decreased by
1 g/dL. In addition, there may be greater varia-
tion between patients with IBD in real-world
clinical practice than in an RCT, and to assess
the importance of this, an analysis was prepared
with the SEs around mean body weight and
hemoglobin increased to 10% of the mean. To
investigate the sensitivity of the analysis to
changes in the pharmacy costs, two analyses
were performed with variation in these model
inputs. In the first, all pharmacy costs were
increased by 10%, while in the second, all
pharmacy costs were decreased by 10%.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not contain any studies with
human participants or animals performed by
any of the authors.
RESULTS
Base Case Analysis
The modeling analysis suggested that FCM was
the most effective intervention, with 81% (SE
2%) of patients with IBD-associated IDA
responding to treatment with this therapy. IIM
and IS were associated with similar efficacy,
with 74% (SE 6%) and 75% (SE 4%) of patients
achieving a response, respectively. A total of
69% (SE 4%) of patients responded to treatment
with oral iron therapy, suggesting that it is the
least effective treatment option. When expres-
sed as number needed to treat in order to
achieve one additional responder with FCM, 16,
17, and 9 patients would need to switch treat-
ment from IIM, IS, and oral iron therapy,
respectively (Fig. 1). Higher number needed to
treat values reflect smaller differences between
the compared groups.
The required dose of iron varied across the IV
iron preparations because of the different cal-
culation methods used. In the FCM arm, a mean
dose of 1364 mg (SE 17 mg) was required,
compared with 1500 mg with both IIM and IS.
However, the mean number of infusions
required to deliver the appropriate dose was
equal in the FCM and IIM arms, with all simu-
lated patients requiring two infusions. In the IS
arm, all patients required eight infusions to
deliver the required dose of iron. Assessment of
costs across the four treatment arms found that
the mean cost of a course of treatment was CHF
461 (EUR 433) with FCM, CHF 485 (EUR 456)
with IIM, CHF 608 (EUR 572) with IS, and CHF
115 (EUR 108) with oral iron therapy. Therefore
FCM was associated with cost savings of CHF 24
(EUR 23) versus IIM and of CHF 147 (EUR 138)
versus IS, and increased costs by CHF 345 (EUR
325) versus oral iron therapy. Cost savings with
FCM were driven by the lower dose of iron
required versus IIM and by the reduced number
of infusions, and therefore reduced requirement
for hospital-based healthcare professional time
and consumables, versus IS.
Combining projections of response rates and
treatment costs showed that FCM was more
effective and less costly than both IIM and IS.
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Therefore, calculation of ICERs was not
required, and FCM was considered dominant
versus both IIM and IS. In the comparison of
oral iron therapy, FCM was associated with an
increased number of responders at an increased
cost, resulting in an ICER of CHF 2970 (EUR
2792) per additional responder (Table 5).
Scenario Analyses
When the Ganzoni formula (instead of the
simplified dosing table) was used to estimate the
required iron dose in the IIM and IS arms, the
required dose fell in both these treatment arms.
The mean number of infusions required with
Fig. 1 Number needed to treat to achieve one additional
responder with ferric carboxymaltose versus other therapy
options. Number needed to treat was expressed as the
number of patients who would need to be treated with
ferric carboxymaltose instead of the comparator in order to
achieve one additional responder. Number needed to treat
values are conventionally rounded up to the next integer
value
Table 5 Results of the base case modeling analysis
Ferric
carboxymaltose
Iron isomaltoside Iron sucrose Oral iron
therapy
Responders (%) 81 (2) 74 (6) 75 (4) 69 (4)
Iron dose (mg) 1364 (17) 1500 (0) 1500 (0) –
Number of infusions 2.0 (0.0) 2.0 (0.0) 8.0 (0.0) –
Cost of treatment (CHF) 461 (3) 485 (0) 608 (0) 115 (0)
Additional cost per additional
responder with ferric
carboxymaltose versus the
comparator
Ferric carboxymaltose
more effective and
less costly
Ferric carboxymaltose
more effective and
less costly
CHF 2970 per
additional
responder
Response was defined as a patient who achieved normalization of hemoglobin levels or an increase in hemoglobin of at least
2 g/dL. Values are mean (standard error)
CHF 2020 Swiss francs
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IIM fell to 1.98 (from 2.00 in the base case) and
the mean number of infusions required to
administer IS fell to 7.02 (from 8.00 in the base
case). The reduced iron dose and the reduced
number of infusions resulted in reduced costs
with IIM and IS compared with the base case
analysis. In this analysis, FCM was associated
with an ICER of CHF 45 (EUR 43) per additional
responder versus IIM, but remained dominant
versus IS (Table 6).
When TARMED codes were used to calculate
costs of treatment, with the Ganzoni formula
applied in the FCM arm and the simplified
dosing table applied in the IIM and IS arms,
costs increased in all treatment arms compared
with the base case, but most markedly in the IS
arm because of the greater number of infusions
required. However, the conclusions of the
analysis did not change compared with the base
case, with FCM remaining dominant versus
both IIM and IS. In the analysis with TARMED
codes used to calculate costs and the Ganzoni
formula used to calculate the iron requirement
in all arms, FCM was associated with an ICER of
CHF 318 (EUR 299) per additional responder
versus IIM and remained dominant versus IS.
Sensitivity Analyses
Sensitivity analyses applying alternative model
inputs found that results remained similar to
the base case analysis (Table 7). When the upper
95% CI of the odds ratio for achieving a
response with each comparator versus FCM was
applied, increased response rates with IIM
Table 6 Scenario analysis results
Additional cost per additional responder with ferric
carboxymaltose versus the comparator
Ferric
carboxymaltose
versus iron
isomaltoside
Ferric
carboxymaltose
versus iron sucrose
Ferric
carboxymaltose
versus oral iron
therapy
Microcosting approach
Base case analysis (Ganzoni formula used in the
ferric carboxymaltose arm, simplified dosing
table used in iron isomaltoside and iron sucrose
arms)
Ferric carboxymaltose
more effective and
less costly
Ferric carboxymaltose
more effective and
less costly
CHF 2970 per
additional
responder
Ganzoni formula used in all arms CHF 45 per
additional
responder
Ferric carboxymaltose
more effective and
less costly
CHF 2970 per
additional
responder
TARMED costing approach
Ganzoni formula used in the ferric carboxymaltose
arm, simplified dosing table used in iron
isomaltoside and iron sucrose arms
Ferric carboxymaltose
more effective and
less costly
Ferric carboxymaltose
more effective and
less costly
CHF 4574 per
additional
responder
Ganzoni formula used in all arms CHF 318 per
additional
responder
Ferric carboxymaltose
more effective and
less costly
CHF 4574 per
additional
responder
Response was defined as a patient who achieved normalization of hemoglobin levels or an increase in hemoglobin of at least
2 g/dL
CHF 2020 Swiss francs
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(86%), IS (81%), and oral iron therapy (79%)
were observed, with the percentage of patients
achieving a response with FCM therapy
remaining unchanged from the base case (81%).
The converse effect was observed when the
lower 95% CI was applied, with the response
rates for IIM, IS, and oral iron therapy falling to
59%, 67%, and 58%, respectively. In these two
analyses, costs remained unchanged from the
base case values, with FCM less costly than
Table 7 Sensitivity analysis results
Additional cost per additional responder with ferric carboxymaltose versus
the comparator
Ferric carboxymaltose
versus iron isomaltoside
Ferric carboxymaltose
versus iron sucrose
Ferric carboxymaltose
versus oral iron
therapy
Base case analysis Ferric carboxymaltose
more effective and less
costly
Ferric carboxymaltose
more effective and less
costly
CHF 2970 per
additional responder
Upper 95% CI of odds ratios Ferric carboxymaltose less
effective and less costly
Ferric carboxymaltose
equally effective and less
costly
CHF 1503 per
additional responder
Lower 95% CI of odds ratios Ferric carboxymaltose
more effective and less
costly
Ferric carboxymaltose
more effective and less
costly
CHF 17,081 per
additional responder
Body weight increased by 10 kg Ferric carboxymaltose
more effective and less
costly
Ferric carboxymaltose
more effective and less
costly
CHF 3291 per
additional responder
Hemoglobin increased by 1 g/dL CHF 1744 per additional
responder
CHF 389 per additional
responder
CHF 2608 per
additional responder
Hemoglobin decreased by 1 g/dL CHF 500 per additional
responder
Ferric carboxymaltose
more effective and less
costly
CHF 3445 per
additional responder
Standard errors around body weight and
hemoglobin equal to 10% of the mean
Ferric carboxymaltose
more effective and less
costly
Ferric carboxymaltose
more effective and less
costly
CHF 2984 per
additional responder
All pharmacy costs ? 10% Ferric carboxymaltose
more effective and less
costly
Ferric carboxymaltose
more effective and less
costly
CHF 3306 per
additional responder
All pharmacy costs - 10% Ferric carboxymaltose
more effective and less
costly
Ferric carboxymaltose
more effective and less
costly
CHF 2646 per
additional responder
Response was defined as a patient who achieved normalization of hemoglobin levels or an increase in hemoglobin of at least
2 g/dL
CHF 2020 Swiss francs, CI credible interval
Adv Ther
either IIM or IS, but more costly than oral iron
therapy.
Increasing the mean patient body weight by
10 kg resulted in an increased iron requirement
in all treatment arms, with mean total doses of
1493 mg with FCM and 2000 mg with IIM and
IS. This resulted in increased costs in all treat-
ment arms compared with the base case analy-
sis. However, the conclusions did not change,
with FCM remaining more effective and less
costly compared with IIM and IS.
In the analysis with baseline hemoglobin
increased by 1 g/dL, the iron requirement was
reduced in all treatment arms. In the FCM arm,
a mean of two infusions was required to provide
the required dose of 1203 mg, but in the IIM
and IS arms the required dose fell to 1000 mg,
requiring one infusion with IIM and five infu-
sions with IS to deliver this dose. In this analy-
sis, FCM was associated with ICERs of CHF 1744
(EUR 1639) per additional responder versus IIM
and CHF 389 (EUR 366) per additional respon-
der versus IS. When the baseline hemoglobin
was decreased by 1 mg/dL, the iron requirement
increased in the FCM arm to 1524 mg, but
remained unchanged in the IIM and IS arms
owing to the use of the simplified dosing table.
Therefore costs increased to CHF 518 (EUR 487)
per patient in the FCM arm, but remained
unchanged with other therapies. FCM was
associated with an ICER of CHF 500 (EUR 470)
per additional responder versus IIM, but
remained dominant versus IS. In the analysis
with increased SEs around baseline body weight
and hemoglobin, similar outcomes to the base
case analysis were projected, but with increased
variation in calculated costs due to a wider
range of iron requirements. The conclusions of
the analysis did not change, with FCM
remaining dominant versus IIM and IS.
Increasing and decreasing the pharmacy
costs by 10% did not change the conclusions of
the analysis. FCM remained dominant versus
IIM and IS in both analyses. Increasing phar-
macy costs resulted in an increased ICER versus
oral iron therapy, while decreasing the phar-
macy costs had the converse effect.
DISCUSSION
Evaluation of the cost-effectiveness of iron
treatments for patients with IDA subsequent to
IBD in Switzerland has suggested that FCM is
the most effective treatment option, associated
with an increased number of responders (de-
fined as patients whose hemoglobin levels are
normalized or increased by at least 2 g/dL)
compared with IIM, IS, and oral iron therapy.
When FCM was compared with IIM, an equal
number of infusions was required with the two
formulations, but FCM was associated with a
lower cost due to the lower required dose as
estimated by the Ganzoni formula (in line with
the Swiss product label for FCM) [17]. When
FCM was compared with IS, the reduction in the
number of required infusions was the key driver
of cost savings with FCM, with this offsetting
the increased pharmacy cost. Reducing the
number of hospital or private practice visits is
an important advantage from a patient per-
spective, as well as reducing costs for healthcare
payers. Data from Switzerland suggest that IDA
is more common in patients with IBD treated in
a hospital outpatient setting than those treated
in private practice, and therefore this informa-
tion is highly pertinent to healthcare providers
and patients accessing care as hospital outpa-
tients [38]. Oral iron therapy is associated with
low pharmacy costs, and the analysis confirmed
that oral iron therapy was less costly than all IV
iron formulations. However, oral iron therapy
was found to be the least effective treatment,
with the lowest response rates. Therefore deci-
sion-making is more complex, and healthcare
providers must assess whether the increased
efficacy of FCM compared with oral iron ther-
apy, and the consequent improvements in
anemia status, with all of the implications for
comorbidities, hospitalization rates, quality of
life, and time lost from work, is worth the
additional cost of CHF 2970 per additional
responder. However, oral iron therapy can be
associated with reduced quality of life and
treatment adherence as it can increase IBD-as-
sociated inflammation and cause mucosal
damage and gastrointestinal symptoms. The
recurrent flares of inflammation and bleeding in
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patients with IBD-related IDA result in patients
requiring repeated courses of iron therapy over
the long term, and therefore choosing a therapy
that is both effective and cost-effective is
important. The ECCO guidelines state that IV
iron therapy should be considered a first-line
treatment in patients with IBD who have clini-
cally active disease, previous intolerance to oral
iron therapy, a hemoglobin level below 10 g/dL,
and in those who need erythropoiesis-stimu-
lating agents [11]. While all patients with IBD
should be routinely monitored for IDA, the
Swiss Inflammatory Bowel Disease Cohort Study
has shown that IDA is more common in female
patients, those with low BMI, malabsorption
syndrome, and those currently using steroids,
and so particular attention should be paid to
patients with IBD with these characteristics
[39].
A recent publication has assessed the cost-
effectiveness of FCM and IIM in the UK setting
based on an indirect treatment comparison,
with a response defined at a hemoglobin change
of at least 2 g/dL [40]. However, the indirect
comparison used in this analysis was not
specific to patients with IDA, as it also included
studies enrolling patients with IDA due to heavy
uterine bleeding and non-dialysis-dependent
chronic kidney disease. The baseline character-
istics used differed from the present analysis in
terms of body weight, with a mean body weight
of 88.3 kg compared with 66.6 kg in the present
analysis. As a result of the differences in dosing
recommendations, with FCM dosage limited to
a maximum of 1000 mg per infusion irrespec-
tive of body weight, while IIM dosing is weight-
based at 20 mg/kg, a higher mean body weight
in the analyzed cohort will favor IIM over FCM.
The analysis in the UK setting is unlikely to be
applicable to the population of patients with
IBD in Switzerland, as it was based on data from
patients with IBD due to a variety of etiologies
and whose body weight is notably higher than
the population of patients with IDA subsequent
to IBD in Switzerland.
The present analysis used an NMA to inform
the differences in efficacy between FCM, IIM, IS,
and oral iron therapy, and this could be con-
sidered a weakness of the analysis [27]. This
approach was chosen as, to date, no head to
head RCT has included all possible treatment
options for patients with IBD subsequent to
IDA, although FCM and IIM were compared in
an observational study conducted in patients
with IBD-related IDA in Norway [21]. The pri-
mary focus of that study was safety, with effi-
cacy measures included as secondary endpoints.
FCM and IIM were also compared in two iden-
tically designed, open-label RCTs with a pre-
specified pooled analysis, but in 68.5% of
enrolled patients the cause of IDA was a gyne-
cological condition, rather than IBD as is of
interest in the present analysis [20]. The limi-
tations of the NMA used to inform the present
analyses have been discussed by the authors of
the NMA in the original publications and in
post-publication correspondence [27, 41–44].
Despite its limitations, the NMA published by
Aksan et al. represents the best available evi-
dence source on differences in clinical out-
comes in patients with IDA and IBD receiving
IV iron therapy.
As part of the systematic review to inform
the NMA, Aksan et al. also collected data on
adverse event rates and found that rates of
adverse events were low with all IV iron prod-
ucts [27]. Infusion site reactions, transient
increases in liver enzymes, headache, hyperfer-
ritinemia, and hypophosphatemia were the
most common adverse events. A more recently
conducted NMA found that the overall inci-
dence of adverse events was similar with all IV
iron treatments, but the most frequently expe-
rienced adverse events differed between treat-
ments [45]. With FCM and IS, the most
common adverse events were headache and
transient hyperferritinemia, while with IIM
they were flushing, hypersensitivity, and hep-
atic enzyme increases. Cost-effectiveness anal-
yses conducted in the future should aim to
capture the impact of adverse events on costs
and clinical outcomes.
The present analysis took a probabilistic
approach, with odds ratios for achieving a
response with IIM, IS, and oral iron therapy
versus FCM sampled in each model iteration.
This approach was chosen to reflect the uncer-
tainty in the clinical outcomes from the NMA,
where FCM was associated with a significantly
greater response rate than oral iron therapy, and
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a numerically greater but not statistically sig-
nificant increase in the number of responders
compared with IIM and IS. As part of the prob-
abilistic approach, patient body weight and
hemoglobin were sampled and the required
iron dose calculated in each model iteration.
These patient characteristics were based on
pooled data from two RCTs [22, 23]. An
important aspect to consider is how the patients
enrolled in these RCTs compare with people
with IDA and IBD in Switzerland. To date, there
is no Switzerland-specific real-world data that
could be compared with the RCTs.
In the present study, costs and responders
were assessed over one cycle of treatment for
IDA, and the impact of retreatment was not
included. Lack of response or recurrence of IDA
due to ongoing IBD inflammation and bleeding
can result in a need for retreatment [46]. If the
requirement for retreatment due to non-re-
sponse were to be included, costs would
increase with all therapies, with the greatest
impact in the least effective treatment arms. If
retreatment related to recurrence of IDA were to
be included, the impact on the additional cost
per additional responder would likely to be
minimal, as recurrence rates would be similar
with all treatment arms leading to similar cost
increases with all therapy options.
One of the key advantages of cost–utility
analyses that assess the cost per additionally
QALY gained is that the ICER produced can be
compared with willingness to pay thresholds to
assess whether a new intervention represents
good value for money versus current practice.
This allows comparison of the impact of multi-
ple new interventions that are used in different
therapeutic areas, as the calculated costs and
quality-adjusted life expectancy can be directly
compared. However, when a ‘‘cost per respon-
der’’ approach is used, no willingness to pay
thresholds have been defined, and this measure
of clinical effectiveness is not applicable to
other therapeutic areas. While the present
analysis is the first to use a cost per responder
approach in patients with IDA subsequent to
IBD in Switzerland, previously published anal-
yses have used this approach in economic
analyses in other therapeutic areas in other
countries, and these can provide context to the
results presented here. The most pertinent
analyses are those conducted in IBD generally.
An analysis of the cost-effectiveness of sele-
nium-75-homocholic acid taurine (SeHCAT) for
investigation of bile acid malabsorption in
chronic diarrhea in the UK setting defined a
responder as a patient for whom diarrhea
resolved [47]. That study found that the results
were highly variable depending on the mod-
elled population, the threshold test result for
further treatment, and the assumptions applied,
with results of between GBP 1208 and GBP
108,412 per additional responder. In the US
setting, an analysis of biologic treatments for
Crohn’s disease assessed responders in terms of
a patient with a decrease in Crohn’s Disease
Activity Index (CDAI) score of at least 70 points
from baseline, and a remitter as a patient with a
CDAI score of less than 150 [48]. Cost per
responder and cost per remitter varied with the
differing interventions, with the modelling
analysis suggesting that the additional cost per
additional responder was USD 116,291 for
adalimumab versus placebo and USD 125,169
for infliximab versus placebo, and that the
additional cost per additional remitter was USD
121,863 for adalimumab versus placebo and
USD 174,846 for infliximab versus placebo.
However, such analyses are not limited to IBD,
with cost per responder analyses previously
conducted to assess the cost-effectiveness of
treatments for glioblastoma, rheumatoid and
psoriatic arthritis, chronic obstructive pul-
monary disease, chronic immune thrombocy-
topenia, and psoriasis [49–53].
CONCLUSIONS
The present cost-effectiveness analysis is the
first study to compare the cost-effectiveness of
IV and oral iron treatment for patients with IDA
subsequent to IBD in Switzerland. The results
suggest that FCM is likely to be the most effec-
tive intervention, with the highest percentage
of patients achieving a response. Furthermore,
FCM was less costly than both IIM and IS. Oral
iron therapy is associated with low pharmacy
costs, and the analysis confirmed that oral iron
therapy was less costly than all IV iron
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formulations. However, oral iron therapy was
found to be the least effective treatment, with
the lowest response rates, and this effect is likely
to be greater in real-world clinical practice
because of the gastrointestinal side effects and
subsequent poor adherence. Oral iron therapy is
a suitable treatment option only for patients
with mild IDA and clinically inactive IBD, with
no history of intolerance to oral iron therapy,
and therefore the target population is likely to
be different to the target population of IV iron
therapies. FCM was projected to be the most
cost-effective IV iron therapy in Switzerland,
increasing the number of responders and lead-
ing to cost savings for healthcare payers.
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